The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10993418 B1

PDF
Full Text
Expired
Date of Patent:
May. 04, 2021

Filed:

Apr. 30, 2018
Applicant:

Life Genetics Lab, Llc, New Orleans, LA (US);

Inventor:

Sudhir Sinha, New Orleans, LA (US);

Assignee:

Other;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12Q 1/6886 (2018.01); C12Q 1/6809 (2018.01); C12Q 1/6827 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6851 (2018.01); A01K 67/027 (2006.01); C12Q 1/6811 (2018.01);
U.S. Cl.
CPC ...
A01K 67/0271 (2013.01); A01K 67/0276 (2013.01); C12Q 1/686 (2013.01); C12Q 1/6809 (2013.01); C12Q 1/6811 (2013.01); C12Q 1/6827 (2013.01); C12Q 1/6886 (2013.01); A01K 2207/12 (2013.01); A01K 2207/15 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0331 (2013.01); C12N 2320/10 (2013.01); C12Q 1/6851 (2013.01); C12Q 2561/101 (2013.01); C12Q 2561/113 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/16 (2013.01);
Abstract

Kits and methods providing measurement of tumor burden in a patient derived xenograft (PDX) mouse are described. Exemplary embodiments contemplate taking a sample, typically a blood sample, from a PDX mouse and using a real-time polymerase chain reaction (PCR) system to quantitate both human patient circulating tumor DNA (ctDNA) and mouse DNA. In preferred embodiments, both PCR amplifications are done simultaneously in a multiplex, and a highly polymorphic human DNA target sequence is amplified for high sensitivity, allowing for small volume samples, typically 50-100 μL, of mouse blood. Serial evaluations are possible because the mouse can survive withdrawal of these small volumes of blood. A related method allows for quantitation of ctDNA in the presence of human immune cells added to a 'humanized' mouse. These relatively quick and easy methods of determining tumor burden in PDX mice can have predictive value for the efficacy of cancer treatments in human patients.


Find Patent Forward Citations

Loading…